Saccharomyces cerevisiae oesophagitis in a patient with oesophageal carcinoma

Journal of Infection in Developing Countries

Volumn 5, Issue 6, 2011, Pages 493-495

  Kliemann, Dimas Alexandre ^a   Antonello, Vicente Sperb ^b   Severo, Luis Carlos ^a,c   Pasqualotto, Alessandro Comarú ^a,d  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Hospital Fêmina   (Brazil)

^c Mycology Laboratory   (Brazil)

^d Molecular Biology Laboratory   (Brazil)

Author keywords

Cancer; Oesophagitis; Opportunistic infections; Probiotics; Saccharomyces; Yeasts

Indexed keywords

FLUCONAZOLE;

ADULT; ANAMNESIS; ANTIBIOTIC SENSITIVITY; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISK DIFFUSION; ESOPHAGITIS; ESOPHAGUS CARCINOMA; HISTOPATHOLOGY; HUMAN; MALE; MYCOSIS; SACCHAROMYCES CEREVISIAE;

CANDIDA; SACCHAROMYCES; SACCHAROMYCES CEREVISIAE;

EID: 79960144661     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.1630     Document Type: Article

References (11)

1. Billoo AG, Memon MA, Khaskheli SA, Murtaza G, Iqbal K, Saeed Shekhani M, Siddiqi AQ. (2006) Role of a probiotic (Saccharomyces boulardii) in management and prevention of diarrhoea. World J Gastroenterol 12: 4557-4560.
2. Salonen JH, Richardson MD, Gallacher K, Issakainen J, Helenius H, Lehtonen OP, Nikoskelainen J. (2000) Fungal colonization of haematological patients receiving cytotoxic chemotherapy: emergence of azole-resistant Saccharomyces cerevisiae. J Hosp Infect 45: 293-301.
3. Munoz P, Bouza E, Cuenca-Estrella M, Eiros JM, Perez MJ, Sanchez-Somolinos M, Rincón C, Hortal J, Peláez T. (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 40: 1625-1634.
4. Konecny P, Drummond FM, Tish KN, Tapsall JW (1999) Saccharomyces cerevisiae oesophagitis in an HIV-infected patient. Int J STD AIDS 10: 821-822.
5. BioMerieux (1993) API ID 32 C-Instruction manual. BioMerieux, Marcy l'Etoile, France.
6. CLSI (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition. CLSI document M27-A2 (ISBN 1-56238-469-4). CLSI, 940 West Valley Road, Suite 1400, Wayne, PA 19087-1898 USA.
7. Eng RH, Drehmel R, Smith SM, Goldstein EJ (1984) Saccharomyces cerevisiae infections in man. Sabouraudia 22: 403-407.
8. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA (2005) Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol 43: 2155-2162.
9. Swinne D, Watelle M, Van der Flaes M, Nolard N (2004) In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study). Mycoses 47:177-183.
10. Tiballi RN, Spiegel JE, Zarins LT, Kauffman CA (1995) Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods. Diagn Microbiol Infect Dis 23: 135-140.
11. Pfaller MA, Messer S, Jones RN (1997) Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 41: 233-235.